Wall Street analysts call the CMS TAVR proposal a "clear positive" for the sector, with Edwards Lifesciences, Medtronic, and ...
On Monday, the Centers for Medicare & Medicaid Services (CMS) proposed removing the coverage with evidence development (CED) ...
The proposed Medicare coverage change could help Edwards Lifesciences gain market share from Medtronic and Boston Scientific, ...
SAN FRANCISCO--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced seven-year data from the PARTNER 3 trial, reaffirming the early and sustained patient benefits of Edwards TAVR. The data ...
Edwards Lifesciences (NYSE: EW) today announced the results from the RHEIA Trial, a first-of-its-kind trial focused exclusively on outcomes for women receiving transcatheter aortic valve implantation ...
The U.S. Food and Drug Administration has approved Edwards Lifesciences' SAPIEN 3 platform, a transcatheter aortic valve replacement (TAVR) therapy, for patients with severe aortic stenosis without ...
MedPage Today on MSN
Balloon-expandable TAVR has struggles evident at 10-year follow-up
Mortality linked to second-generation Sapien XT in intermediate surgical risk cohort ...
Irvine-based Edwards Lifesciences Corp. recently shared data on yet another potential market for its Edwards Sapien less-invasive replacement heart valve. Data analysis from the company’s Partner ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results